X
XNK Therapeutics
Autologous natural killer cell-based cancer immunotherapies
About XNK Therapeutics
XNK Therapeutics AB was a clinical-stage immunotherapy company founded in 2012 in Huddinge, Sweden, that focused on developing novel, autologous natural killer (NK) cell-based therapies for cancer treatment. The company, formerly known as Cell Protect Nordic Pharmaceuticals, developed a proprietary technology platform to expand and activate a patient's own NK cells to target cancers. Its operations spanned both hematological malignancies and solid tumor indications.
The company's lead drug candidate was CellProtect, and its product pipeline included ACP-001 and ISA-HC-NK. Their most advanced product, evencaleucel, was in phase II studies for treating multiple myeloma. Other programs in preclinical stages included XNK02 for acute myeloid leukemia (AML), XNK03 for bladder cancer, and XNK04 for hepatocellular carcinoma (liver cancer), often in collaboration with institutions like the MD Anderson Cancer Center and the Karolinska University Hospital. XNK Therapeutics operated its own in-house GMP facility.
Over its lifetime, the company secured funding through various rounds, including a grant of $110K in 2018, an angel round of $7.44M in 2021, and a Series B round of $13.9M on March 29, 2022, led by Flerie. Despite these efforts and receiving a scientific recommendation from the European Medicines Agency's (EMA) Committee for Advanced Therapies for its product Evencaleucel, the company faced financial difficulties. On April 9, 2024, XNK Therapeutics AB was declared bankrupt. Following the bankruptcy, the company's assets, including its GMP facility and intellectual property, were sold off.
Source: Dealroom company dataNews
Open roles
XNK Therapeutics in the Huddinge kommun ecosystem
The XNK Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Vinnova
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about XNK Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See XNK Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


